4,116 results match your criteria Clinical Lymphoma Myeloma & Leukemia [Journal]


Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Jan 3. Epub 2019 Jan 3.

Adult Hematologic Malignancies and Stem Cell Transplant Program, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH; Case Western Reserve University School of Medicine, Cleveland, OH. Electronic address:

Background: High-dose chemotherapy and autologous stem cell transplantation (ASCT) are integral components of the overall treatment for patients with multiple myeloma (MM) aged ≤ 65 years. The emergence of oligoclonal immunoglobulin bands (ie, immunoglobulins differing from those originally identified at diagnosis [termed clonal isotype switch (CIS)]) has been reported in patients with MM after high-dose chemotherapy followed by autologous stem cell transplantation. However, the clinical relevance and the correlation with immune reconstitution remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.022DOI Listing
January 2019

Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Department of Radiation Oncology, Mount Sinai Hospital, New York, NY.

Background: Given the rarity of plasmacytoma, large-scale database analysis can provide useful information regarding the clinical presentation and patient-related factors impacting overall survival (OS).

Materials And Methods: The National Cancer Data Base was queried for patients with plasmacytoma between 2004 and 2013, excluding patients with systemic disease. Plasmacytomas were classified as originating in bone (P-bone), in extramedullary tissue (P-EM), or unspecified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.004DOI Listing
January 2019

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

Moffitt Cancer Center and Research Institute, Tampa, FL.

Purpose: To test the hypothesis that combination treatment with lenalidomide and prednisone will yield a higher erythroid response rate in patients with non-del(5q) lower-risk myelodysplastic syndromes compared to the historical clinical trial data with lenalidomide monotherapy, which reported a 26% transfusion independence rate.

Patients And Methods: The study enrolled 25 patients with lower-risk myelodysplastic syndromes by the International Prognostic Scoring System who were transfusion dependent or who had symptomatic anemia and prior erythroid stimulating agent failure or low chance of response. The planned dose of lenalidomide was 10 mg per day. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.014DOI Listing
January 2019
2 Reads

Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected.

Leuk Lymphoma 2019 Mar 7:1-8. Epub 2019 Mar 7.

b Stem Cell Transplant Program University Hospitals Seidman Cancer Center Case Comprehensive Cancer Center and Case Western Reserve University , Cleveland , OH , USA.

Lenalidomide (LEN) is commonly used as part of induction therapy in transplant-eligible patients with multiple myeloma. However, LEN use is associated with increased chance of peripheral blood stem cell (PBSC) collection failure. This has led to early collection in patients receiving induction with LEN-containing regimens, and the use of mobilization agents such as plerixafor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573367DOI Listing
March 2019
2 Reads

Mortality of lymphoma and myeloma in China, 2004-2017: an observational study.

J Hematol Oncol 2019 Mar 4;12(1):22. Epub 2019 Mar 4.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.

Background: There is a dearth of accurate information about patterns of mortality of lymphoid neoplasms and temporal trends in China. In this nationwide mortality study, we aimed to assess the mortality of lymphoma and myeloma in 2017 and the changes in the trend from 2004 to 2016.

Methods: Death certificate data obtained from the Chinese Center for Disease Control and Prevention's disease surveillance points system (CDC-DSP) and population data from the National Bureau of Statistics of China were used in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0706-9DOI Listing
March 2019
1 Read

Integration of Transcriptional and Mutational Data Simplifies the Stratification of Peripheral T-Cell Lymphoma.

Am J Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities like angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. Herein, to improve the current molecular classification between AITL and PTCL-NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their molecular configuration and integrated them with genomic data of recurrently mutated genes (RHOA , TET2, IDH2 , DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included in the series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25450DOI Listing
March 2019
1 Read

Exosomes from Cell Culture-Conditioned Medium: Isolation by Ultracentrifugation and Characterization.

Methods Mol Biol 2019 ;1952:233-244

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Exosomes are small vesicles of endosomal origin secreted by most cell types. Recent studies have identified exosomes as important mediators of intercellular communication and as important source materials for many clinical applications, including minimal invasive disease diagnosis. Exosomes have been purified from in vitro cell culture supernatants by many different methods; however the most simple and reliable method involves purification by ultracentrifugation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9133-4_19DOI Listing
January 2019

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.

Eur J Haematol 2019 Feb 22. Epub 2019 Feb 22.

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Objective: Despite long-standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B-cell lymphoproliferative diseases are limited. Here we examine the correlation between approved IgRT indications, treatment recommendations and clinical practice in SID.

Methods: An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13223DOI Listing
February 2019
2 Reads

The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Front Immunol 2019 8;10:33. Epub 2019 Feb 8.

Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies. Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas secondary antibody deficiency may arise as a consequence of underlying conditions or medication use. On a global level, malnutrition, HIV, and malaria are major causes of secondary immunodeficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376447PMC
February 2019
2 Reads

Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Jan 29. Epub 2019 Jan 29.

Department of Biochemistry, University Hospital of Nantes, Nantes, France.

Background: Serum free light chain (FLC) measurement has become an important marker for the management of multiple myeloma (MM). However, several analytical challenges remain unresolved. We compared the clinical performances of the Sebia FLC assay in MM to the Freelite assay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.007DOI Listing
January 2019
1 Read

Inheritance of Susceptibility to Malignant Blood Disorders.

Sci Rep 2019 Feb 21;9(1):2444. Epub 2019 Feb 21.

Department of Hematology, Oslo University Hospital, KG Jebsen Center for B cell malignancies P.O. box 4950, Nydalen, NO 0424, Oslo, Norway.

Malignant blood disorders depend on heritable susceptibility genes and occur in familial aggregations. We suggest a model of transgenerational segregation of the susceptibility genes based on the study of malignant blood disorders in Norwegian and Danish families with unrelated parents, and in the inbred Faroese population with related parents. This model, consisting of parental genomic imprinting and mother-son microchimerism, can explain the male predominance in most of the diseases, the predominance of affected parent-offspring when parents are not related, and the different modes of segregation in males and females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38879-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385281PMC
February 2019
1 Read

Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.

Introduction: The clinical application of the Revised International Staging System (R-ISS) for multiple myeloma may be limited by heterogeneity in clinical interphase fluorescent in situ hybridization (FISH) practices for detecting chromosomal abnormalities (CAs). Next generation sequencing (NGS)-based FISH (Seq-FISH) has demonstrated improved sensitivity and similar specificity relative to clinical FISH, and provides a standardized, single-pass method for identifying high-risk CAs. To date, calculating R-ISS stage using Seq-FISH (R-ISS-NGS) has not been validated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.003DOI Listing
January 2019
1 Read

Vitamin A and Hydrochlorothiazide Causing Severe Hypercalcemia in a Patient With Primary Hyperparathyroidism.

J Investig Med High Impact Case Rep 2019 Jan-Dec;7:2324709618823805

2 CHI Little Rock Diagnostic Clinic, Little Rock, AR, USA.

Objective: To report a case of severe hypercalcemia, exacerbated by vitamin A supplementation and hydrochlorothiazide, in a patient with primary hyperparathyroidism.

Methods: Clinical and laboratory findings are presented along with response to therapy.

Results: A 68-year-old white female presented to the emergency department complaining of nausea, vomiting, and altered mental status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2324709618823805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350155PMC
February 2019
2 Reads

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019
2 Reads

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Leuk Lymphoma 2019 Feb 19:1-12. Epub 2019 Feb 19.

c Cabrini Health , Australia and Monash University , Melbourne , Australia.

Efficacy and safety of bortezomib-based consolidation following ASCT were investigated in newly diagnosed multiple myeloma patients from Australia, Korea, and China. Patients received three cycles of bortezomib-cyclophosphamide-dexamethasone induction followed by high-dose therapy/ASCT, then were randomized (1:1) to consolidation with TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n = 100) or VTP (subcutaneous bortezomib 1.3 mg/m every 2 weeks for 32 weeks, plus TP; n = 103). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579322DOI Listing
February 2019
5 Reads

Evaluating the role of Tregs in the progression of multiple myeloma.

Leuk Lymphoma 2019 Feb 18:1-9. Epub 2019 Feb 18.

c Leukemia/BMT Program of BC, British Columbia Cancer Agency , University of British Columbia , Vancouver , BC , Canada.

The role of regulatory T-cells (Treg) and Th17 cells in the progression of multiple myeloma has been unclear. There are conflicting reports of the Treg and Th17 frequency being increased, decreased, and unchanged as compared with controls. In this study, we sought to characterize the T-cell subsets including Treg function in both blood and marrow compartments of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579324DOI Listing
February 2019
1 Read

Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Stem Cell and Cancer Institute, Jakarta, Indonesia; Kalbe Genomics Laboratory, Jakarta, Indonesia.

Background: Defining the presence of BCR-ABL transcript in suspected myeloproliferative neoplasm is essential in establishing chronic myeloid leukemia. In the absence of BCR-ABL, the conventional diagnostic algorithm recommends JAK2 V617F mutation testing to support diagnosis of other MPN diseases such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis. In certain cases of thrombocythemia, simultaneous upfront testing of both BCR-ABL and JAK2 may be desirable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.005DOI Listing
January 2019
2 Reads

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.

Clin Lymphoma Myeloma Leuk 2018 Dec 21. Epub 2018 Dec 21.

MDS Unit, AOU Careggi, University of Florence, Florence, Italy.

Background: In the phase III MDS-005 study of patients with lower-risk, non-del(5q) myelodysplastic syndromes, lenalidomide was associated with a higher rate of ≥ 8 weeks red blood cell transfusion independence (RBC-TI) compared with placebo, but also with a higher risk of hematologic adverse events (AEs).

Patients And Methods: This analysis evaluated the ratio of clinical benefit-risk in patients treated with lenalidomide or placebo, and assessed the effect of lenalidomide dose reductions on response. Clinical benefit was a composite endpoint defined as RBC-TI, transfusion reduction ≥ 4 units packed red blood cells, hemoglobin increase ≥ 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.012DOI Listing
December 2018
1 Read

Adding Oral Pioglitazone to Standard Induction Chemotherapy of Acute Myeloid Leukemia: A Randomized Clinical Trial.

Clin Lymphoma Myeloma Leuk 2019 Jan 19. Epub 2019 Jan 19.

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Background: The hypothesis of an effect by thiazolidinedione on leukemia cells was proposed 2 decades ago, but there is little clinical evidence regarding its efficacy. We evaluated the safety and efficacy of adding pioglitazone to standard induction chemotherapy in patients with acute myeloid leukemia (AML).

Patients And Methods: In this randomized clinical trial, newly diagnosed AML patients were randomized to 1 of 2 groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.01.006DOI Listing
January 2019

Immune profiling and quantitative analysis decipher the clinical role of immune checkpoint expression in the tumor immune microenvironment of DLBCL.

Cancer Immunol Res 2019 Feb 11. Epub 2019 Feb 11.

Hematopathology, The University of Texas MD Anderson Cancer Center

PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for twelve types of cancer and are being studied in diffuse large B-cell lymphoma (DLBCL), the most common aggressive B-cell lymphoma. However, whether both PD-1 and CTLA-4 checkpoints are active and clinically significant in DLBCL is unknown. Whether PD-1 ligands expressed by tumor cells or by the microenvironment of DLBCL are critical for immune checkpoint is unclear. Read More

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0439DOI Listing
February 2019
5 Reads

Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

University of Arizona, Tucson, AZ.

Background: Serum copper has been reported to be increased in various cancers, including lymphoma. The purpose of the present study was to investigate the clinical and prognostic importance of serum copper levels in patients with cutaneous T-cell lymphoma (CTCL).

Patients And Methods: Serum copper was measured in 60 men and 38 women with mycosis fungoides (MF) and 14 men and 3 women with erythrodermic CTCL (6 with Sézary syndrome) consecutively evaluated from July 1980 to June 1985. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183144
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.020DOI Listing
January 2019
6 Reads

Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Feb 5. Epub 2019 Feb 5.

Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark; Institute for Inflammation Research, University Hospital Rigshospitalet, Copenhagen, Denmark.

Autologous stem cell transplantation (ASCT) is challenged by side effects that may be propagated by chemotherapy-induced mucositis, resulting in bacterial translocation and systemic inflammation. Because gastrointestinal damage appears as an early event in this cascade of reactions, we hypothesized that markers reflecting damage to the intestinal barrier could serve as early predictive markers of toxicity. Glucagon-like peptide-1 (GLP-1), a well-known regulator of blood glucose, has been found to promote intestinal growth and repair in animal studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.036DOI Listing
February 2019

Cryoglobulinemia: An update in 2019.

Joint Bone Spine 2019 Feb 4. Epub 2019 Feb 4.

Sorbonne universités, UPMC Université Paris 06, Inserm, UMR S 959, immunology immunopathology immunotherapy (I3), 75005, Paris, France; Biotherapy (CIC-BTi) and inflammation-immunopathology-biotherapy department (DHU i2B), hôpital Pitié-Salpêtrière, AP-HP, 75651, Paris, France; AP-HP, groupe hospitalier Pitié-Salpêtrière, department of internal medicine and clinical immunology, centre national de référence maladies autoinflammatoires et amylose inflammatoire, centre national de références maladies autoimmunes systémiques rares, 75013, Paris, France. Electronic address:

Cryoglobulinemia is defined as the persistent presence in serum of abnormal immunoglobulins (Igs) that precipitate at low temperatures and dissolve again upon warming. Cryoglobulins may be composed only of a monoclonal Ig (simple type I cryoglobulinemia), of a monoclonal Ig bound to the constant domain of polyclonal Ig heavy chains (mixed type II cryoglobulinemia), or only of polyclonal Igs (mixed type III cryoglobulinemia). The manifestations of type I cryoglobulinemia are often related to intravascular obstruction, whereas those seen in the mixed cryoglobulinemias often originate in true immune complex-mediated vasculitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2019.01.016DOI Listing
February 2019
10 Reads

Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.

Sci Signal 2019 Feb 5;12(567). Epub 2019 Feb 5.

Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard Unit 0429, Houston, TX 77030-4009, USA.

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma that is largely chemoresistant. Ibrutinib, a drug that inhibits Bruton's tyrosine kinase (BTK), has improved the overall survival of patients with MCL; however, resistance to ibrutinib has emerged as a decisive, negative factor in the prognosis of MCL. Adopting a more patient-centric therapeutic approach that incorporates applied genomics and interrogation of B cell signaling pathways may offer an alternative route to reach durable remission in patients with MCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aat4105DOI Listing
February 2019
2 Reads
6.279 Impact Factor

Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Blood 2019 Feb 5. Epub 2019 Feb 5.

James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, United States.

Serum soluble chemokines/cytokines produced by Hodgkin-cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum TARC, MDC, IL10, and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (FDG-PET), and post-therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET(PET2)-positive patients (ClinicalTrials.gov Identifier: NCT00822120). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-870915DOI Listing
February 2019
2 Reads

Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.

Clin Lymphoma Myeloma Leuk 2018 Dec 20. Epub 2018 Dec 20.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

Introduction: The combination of lenalidomide and dexamethasone (Len-Dex) is an established regimen for patients with relapsed or refractory myeloma. To prolong the benefit of this effective regimen, the Myeloma Program at Princess Margaret Cancer Centre has routinely added a third agent, oral cyclophosphamide (Cy) given weekly, to Len-Dex at disease progression.

Patients And Methods: In the present report, we describe the cases of 53 patients who had received Len-Dex-Cy for a minimum of 4 weeks from January 2007 to December 2014 after progression with Len-Dex alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.007DOI Listing
December 2018
2 Reads

Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20 multiple myeloma.

Leuk Lymphoma 2019 Feb 5:1-3. Epub 2019 Feb 5.

a Department of Internal Medicine III, Hematology & Oncology , University Hospital of Regensburg , Regensburg , Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1571200DOI Listing
February 2019

Is there a role for proton pump inhibitor prophylaxis in haematology patients?

Intern Med J 2019 Feb 5. Epub 2019 Feb 5.

Department of Clinical Haematology, Austin Hospital, Melbourne, Victoria.

While proton pump inhibitors (PPIs) are widely prescribed as prophylaxis in selected haematology inpatient and outpatients , an informal survey of haematology units around Australia found wide variations in the specific indications for their use. This is consistent with a literature review which showed a paucity of robust evidence to support their use, specifically in chemotherapy-induced mucositis, thrombocytopenia or administration of high dose glucocorticosteroids in the absence of additional risk factors. Overuse is relevant both due to cost perspective emerging evidence of adverse events associated with prolonged PPI administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imj.14241DOI Listing
February 2019
1 Read

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Curr Oncol Rep 2019 Feb 4;21(2):17. Epub 2019 Feb 4.

Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.

Purpose Of Review: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.

Recent Findings: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0759-5
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0759-5DOI Listing
February 2019
10 Reads

Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature.

Clin Lymphoma Myeloma Leuk 2019 Mar 3;19(3):183-189.e1. Epub 2019 Jan 3.

Clinical Hematology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Electronic address:

Background: Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.003DOI Listing
March 2019
3 Reads

A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison.

Clin Lymphoma Myeloma Leuk 2018 Dec 20. Epub 2018 Dec 20.

Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.

Background: The incidence of peripherally inserted central catheter (PICC)-related adverse events has been uncertain in the setting of acute myeloid leukemia (AML) compared with the incidence of centrally inserted central catheter (CICC) adverse events.

Patients And Methods: We conducted a monocentric, randomized trial of patients with previously untreated AML. Of the 93 patients, 46 had received a PICC and 47 had received a CICC as frontline intravascular device. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183154
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.008DOI Listing
December 2018
5 Reads

Lenalidomide-related Progressive Multifocal Leukoencephalopathy: A Case Report and Review of Drug-related Cases in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Jan 3. Epub 2019 Jan 3.

Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia; Bosch Institute, The University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.021DOI Listing
January 2019
1 Read

Aerobic physical exercise for adult patients with haematological malignancies.

Cochrane Database Syst Rev 2019 01 31;1:CD009075. Epub 2019 Jan 31.

Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, Germany.

Background: Although people with haematological malignancies have to endure long phases of therapy and immobility, which is known to diminish their physical performance level, the advice to rest and avoid intensive exercises is still common practice. This recommendation is partly due to the severe anaemia and thrombocytopenia from which many patients suffer. The inability to perform activities of daily living restricts them, diminishes their quality of life and can influence medical therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD009075.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354325PMC
January 2019
2 Reads

Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: A qualitative study.

Palliat Med 2019 Jan 30:269216318824525. Epub 2019 Jan 30.

1 Epidemiology and Cancer Statistics Group, University of York, York, UK.

Background:: People with haematological malignancies have different end-of-life care patterns from those with other cancers and are more likely to die in hospital. Little is known about patient and relative preferences at this time and whether these are achieved.

Aim:: To explore the experiences and reflections of bereaved relatives of patients with leukaemia, lymphoma or myeloma, and examine (1) preferred place of care and death; (2) perceptions of factors influencing attainment of preferences; and (3) changes that could promote achievement of preferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216318824525DOI Listing
January 2019

Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.

Clin Lymphoma Myeloma Leuk 2019 Jan 2. Epub 2019 Jan 2.

Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA.

Background: Few studies have evaluated real-world treatment patterns and survival in follicular lymphoma (FL). This study evaluated these outcomes among newly diagnosed patients with FL in routine clinical care.

Patients And Methods: A retrospective study was conducted in newly diagnosed patients with FL from Humedica, a large United States electronic medical record database, from January 1, 2008 to July 31, 2015. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183112
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.017DOI Listing
January 2019
4 Reads

New Drugs in Multiple Myeloma.

Annu Rev Med 2019 Jan;70:521-547

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email:

Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-112017-091045DOI Listing
January 2019
1 Read

Outcome of Childhood Acute Megakaryoblastic Leukemia: Children's Cancer Hospital Egypt 57357 Experience.

Clin Lymphoma Myeloma Leuk 2019 Mar 20;19(3):e142-e152. Epub 2018 Dec 20.

Department of Pediatric Oncology, Children's Cancer Hospital Egypt (CCHE 57357), Cairo, Egypt; Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.

Introduction: Acute megakaryoblastic leukemia is a rare subtype of pediatric acute myeloid leukemia (AML) with poor outcomes in patients with non-Down syndrome. The reported outcomes have been poor, and the prognostic factors have not been clearly determined.

Patients And Methods: To evaluate the prognostic significance of various cytogenetic abnormalities and minimal residual disease status determined by flow cytometry after induction I, we retrospectively analyzed the data of 80 patients with non-Down syndrome with a diagnosis of M7 AML treated at Children's Cancer Hospital Egypt (CCHE-57357) from July 2007 through December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.011DOI Listing
March 2019
2 Reads

Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.

Clin Lymphoma Myeloma Leuk 2019 Jan 3. Epub 2019 Jan 3.

Winship Cancer Institute of Emory University, Atlanta, GA.

Background: Disease progression within < 2 years of initial chemoimmunotherapy and patient age > 60 years have been associated with poor overall survival (OS) in follicular lymphoma (FL). No standard treatment exists for these high-risk patients, and the effectiveness of sequential therapies remains unclear.

Patients And Methods: We studied the course of FL with first-, second-, and third-line treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.019DOI Listing
January 2019
1 Read

G-CSF administration favours SDF-1 release and activation of neutrophils and monocytes in recipients of autologous peripheral blood progenitor cells.

Cytokine 2019 Apr 24;116:38-47. Epub 2019 Jan 24.

Laboratory of Clinical Immunogenetics and Pharmacogenetics, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroclaw, Poland; Department of Internal Diseases, Occupational Medicine, Hypertension and Clinical Oncology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland.

G-CSF is a growth factor widely used to mobilise CD34+ progenitor cells for clinical applications. The present study aimed to assess expression of G-CSF receptor (CSF3R) on neutrophils and monocytes, as well as SDF-1 and G-CSF serum levels in relation to efficacy of G-CSF-induced mobilisation for autologous transplantation. For this purpose, 105 patients with haematological disorders and 46 healthy controls were investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2018.12.011DOI Listing
April 2019
9 Reads

Prognostic Value of 1q21 Gain in Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Mar 20;19(3):e159-e164. Epub 2018 Dec 20.

Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, People's Republic of China. Electronic address:

Background: Multiple myeloma (MM) is a heterogeneous disease characterized by chromosomal translocation, deletion, and amplification in plasma cells, resulting in a huge heterogeneity in its outcomes. In the era of novel agents such as bortezomib, thalidomide, and the cycles of treatment, risk stratification by chromosomal aberrations may enable a more rational risk-stratification selection of therapeutic approaches in patients with MM.

Patients And Methods: We performed a retrospective study in 63 patients with MM; 29 (46. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.12.002DOI Listing
March 2019
1 Read

Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma.

Aliment Pharmacol Ther 2019 Mar 25;49(5):589-598. Epub 2019 Jan 25.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Background: Chronic hepatitis B has been linked to lymphoma with contradictory results.

Aim: To investigate the association between chronic hepatitis B and lymphoma by using a nationwide population-based cohort.

Methods: Records of patients diagnosed with chronic hepatitis B (hepatitis B virus [HBV] cohort) or without (non-HBV cohort) during 2004-2007 were retrieved from the Taiwan National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.15132DOI Listing
March 2019
1 Read

Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.

Br J Clin Pharmacol 2019 Jan 22. Epub 2019 Jan 22.

Australian Centre for Pharmacometrics, School of Pharmacy and Medical Sciences, Division of Health Sciences, University of South Australia, Australia.

Aims: Lenalidomide is an immunomodulatory imide drug used broadly in the treatment of multiple myeloma and lymphoma. It continues to be evaluated in chronic lymphocytic leukaemia (CLL) at lower doses due to dose-related toxicities including tumour flare and tumour lysis syndrome. This study aimed to develop a population pharmacokinetic model for lenalidomide in multiple cancers, including CLL, to identify any disease-related differences in disposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bcp.13873DOI Listing
January 2019
1 Read

Acalabrutinib for adults with mantle cell lymphoma.

Expert Rev Clin Pharmacol 2019 Mar 26;12(3):179-187. Epub 2019 Jan 26.

b Department of Lymphoma and Myeloma , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

Introduction: Although advances in mantle cell lymphoma (MCL) therapy have improved overall survival (OS), managing relapsed/refractory (R/R) cases remains a great challenge. Bruton tyrosine kinase (BTK) inhibitors have broadened therapeutic options in MCL and became the backbone of second-line strategies. Areas covered: Ibrutinib, the first-in-class BTK inhibitor registered for MCL therapy, is efficient, with clear benefits of its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1568868DOI Listing
March 2019
15 Reads

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Leuk Lymphoma 2019 Jan 11:1-9. Epub 2019 Jan 11.

b Genomic Epidemiology Group, German Cancer Research Center (DKFZ) , Heidelberg , Germany.

Genetic variants in genes acting during the maturation process of immature B-cell to differentiated plasma cell could influence the risk of developing multiple myeloma (MM). During B-cell maturation, several programmed genetic rearrangements occur to increase the variation of the immunoglobulin chains. Class switch recombination (CSR) is one of the most important among these mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1551536DOI Listing
January 2019
5 Reads

Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients.

Leuk Lymphoma 2019 01 10:1-10. Epub 2019 Jan 10.

a Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.

In the era of an aging population, an increasing number of patients are diagnosed with multiple myeloma at an age of ≥80. The frailty of this population as a result of coexisting comorbidities and age-related organ impairment is a significant management challenge. The aim of our study was to analyze the disease characteristics, frailty scores and toxicity profile in relation to patient outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1509323DOI Listing
January 2019
1 Read

Adoptive cell therapy for acute myeloid leukemia.

Leuk Lymphoma 2019 Jan 10:1-11. Epub 2019 Jan 10.

a Department of Hematology , West China Hospital, Sichuan University , Chengdu , China.

Acute myeloid leukemia (AML) is the most common tumor in adult patients, most of the patients have a poor prognosis even after high-intensity chemotherapy, especially for relapsed, refractory or elderly patients. Therefore, new methods are needed to change the outcomes. In recent years, an increasing number of immune-therapies are emerging where adoptive cell therapy, a special immunotherapy, has become a promising strategy for AML. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1553300DOI Listing
January 2019
6 Reads

Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma?

Leuk Lymphoma 2019 Jan 10:1-7. Epub 2019 Jan 10.

a Department of Hematology , Shengjing Hospital of China Medical University , Shenyang , China.

Multiple myeloma (MM) patients are immunodeficient. Complement C1q is an important cofactor of both nonspecific and humoral immunity, and it participates in the immunomodulation of multiple tumors. Thus, this study aimed to determine the risk factors and clinical significance of C1q expression in MM patients. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1543883DOI Listing
January 2019
8 Reads

Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2019 Mar 6;19(3):177-182. Epub 2018 Dec 6.

Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Turkey.

Background: Refractory acute myeloid leukemia (AML) includes AML includes failure of disease to respond to standard induction chemotherapy, relapse within 6 months after first CR, and 2 or more relapses. The outcome of these patients is usually very poor; only a small proportion can be rescued by allogenic hematopoietic stem-cell transplantation (allo-HSCT). The aim of this study was to evaluate the efficacy and feasibility of allo-HSCT in patients with refractory AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.016DOI Listing
March 2019
1 Read

Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.

Int J Cancer 2019 Jan 7. Epub 2019 Jan 7.

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Overweight/obesity, adult attained height and physical activity are possible risk factors for hematological malignancies. This meta-analysis aims to evaluate the associations between these factors and hematological cancer risk in adults. Eligible cohort studies were sought in PubMed up to May 31, 2016; overall, 44 studies were included in the present analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32109DOI Listing
January 2019
3 Reads

Ixazomib - the first oral proteasome inhibitor.

Leuk Lymphoma 2019 Jan 7:1-9. Epub 2019 Jan 7.

a College of Pharmacy , Jinan University , Guangzhou , PR China.

Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015. With a promising effect in prolonging the progression-free survival compared with placebo treatment (median: 20. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1523398DOI Listing
January 2019
16 Reads